CD274 and intrahepatic cholangiocarcinoma: Clinical evidence supports aberrant PD-L1 expression in tumor cells, which aids in their escape from T cell immune attack in non-small-cell lung cancer (NSCLC), renal cell carcinoma, Hodgkin’s lymphoma, hepatocellular carcinoma (HCC), and intrahepatic cholangiocarcinoma (ICC) (10).